AGIOAGIOS PHARMACEUTICALS, INC.vs its industry peers
A metric-by-metric comparison of AGIOS PHARMACEUTICALS, INC. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AGIO본 종목 | $2.0B#8 | — | 2.0x#5 | 37.6x#9 | 48.0%#5 | -161.3%#13 | -873.9%#11 | -40.3%#9 | — | — | -6.4%#10 | — |
| PBH | $2.2B#2 | 13.0x#1 | 1.1x#2 | 2.0x#4 | -4.3%#12 | -11.3%#10 | 28.4%#1 | 9.9%#2 | 5.9%#2 | 4#1 | -27.4%#12 | — |
| TRVI | $2.2B#1 | — | 6.9x#10 | — | — | 10.7%#9 | — | -13.3%#6 | — | — | 94.0%#3 | — |
| SRPT | $2.2B#3 | — | 1.4x#3 | 1.2x#3 | 4.3%#10 | -403.3%#14 | -37.5%#6 | -46.7%#10 | -73.0%#6 | — | 21.5%#9 | — |
| ZBIO | $2.2B#4 | — | 8.8x#12 | 217.6x#11 | 100.0%#4 | -140.6%#12 | -3830.6%#12 | -152.9%#14 | -296.6%#8 | — | 74.7%#5 | — |
| BHC | $2.1B#5 | — | — | 0.2x#1 | 6.7%#9 | 441.3%#2 | 17.7%#2 | — | 3.6%#3 | — | — | 16.6%#1 |
| NUVB | $2.1B#6 | — | 8.4x#11 | 34.0x#8 | 699.0%#2 | 64.0%#4 | -338.7%#10 | -80.6%#12 | -87.4%#7 | — | 85.7%#4 | — |
| RAPP | $2.0B#7 | — | 4.8x#8 | — | — | -42.4%#11 | — | -26.4%#8 | — | — | 61.6%#7 | — |
| ZYME | $2.0B#10 | — | 24.5x#13 | 18.6x#7 | 38.9%#7 | 33.9%#6 | -87.3%#7 | -100.9%#13 | — | — | 74.5%#6 | — |
| BHVN | $2.0B#9 | — | 162.9x#14 | — | — | 12.7%#8 | — | -6045.0%#15 | — | — | -10.5%#11 | — |
| PRGO | $1.9B#13 | — | 0.7x#1 | 0.4x#2 | -2.8%#11 | -729.7%#15 | -26.4%#5 | -56.7%#11 | -20.9%#4 | 4#1 | -31.4%#13 | 8.6%#2 |
| SEPN | $1.9B#12 | — | 4.8x#7 | 40.5x#10 | 4174.5%#1 | 31.9%#7 | -148.6%#9 | -12.6%#5 | — | — | 176.5%#1 | — |
| STOK | $1.9B#11 | — | 5.4x#9 | 10.1x#5 | 404.5%#3 | 92.3%#3 | -11.2%#4 | -2.0%#4 | — | — | 27.3%#8 | — |
| XNCR | $1.8B#14 | — | 3.6x#6 | 14.6x#6 | 13.7%#8 | 60.5%#5 | -141.4%#8 | -18.3%#7 | -31.5%#5 | — | 164.9%#2 | — |
| KLRA | $1.7B#15 | — | 1.5x#4 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ANIP | — | 16.3x#2 | — | — | 43.8%#6 | 510.5%#1 | 12.6%#3 | 13.1%#1 | 16.9%#1 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice